Prehabilitation of the respiratory muscles has emerged as a critical component in the perioperative management of patients undergoing high-risk surgical procedures. Accumulating evidence suggests that targeted respiratory muscle training, initiated prior to surgery, can significantly reduce postoperative pulmonary complications, shorten hospital stays, and enhance overall recovery. This review synthesizes current research, highlights underlying mechanisms, discusses risk stratification, evaluates clinical implementation, and presents the latest guideline recommendations to inform best practices among clinicians managing high-risk surgical candidates.
High-risk surgeries, particularly those involving the thoracic and upper abdominal regions, are frequently complicated by postoperative pulmonary complications (PPCs) such as atelectasis, pneumonia, and respiratory failure. These complications contribute to increased morbidity, prolonged hospitalization, and elevated healthcare costs. Respiratory muscle prehabilitation—defined as structured, preoperative training to enhance the strength and endurance of respiratory musculature—offers a promising strategy to mitigate these risks. This article aims to provide a comprehensive overview of the role and impact of respiratory muscle prehabilitation in patients undergoing high-risk surgical interventions, emphasizing the clinical rationale, supporting evidence, and practical considerations for its integration into perioperative care.
PPCs remain a substantial concern in surgical populations, with reported incidences ranging from 5% to 40% depending on operative type, patient characteristics, and perioperative management. Major risk factors include advanced age, pre-existing respiratory disease, obesity, and functional impairment, all of which are commonly encountered in high-risk surgical cohorts. The incidence of PPCs is particularly high following cardiothoracic and upper abdominal procedures, where diaphragmatic dysfunction and impaired cough reflex are prevalent. These complications are associated with significant increases in hospital length of stay, intensive care requirements, and mortality rates, underscoring the need for effective preventive strategies such as prehabilitation.
Surgical trauma, anesthesia, and postoperative pain can severely compromise respiratory mechanics. Both general anesthesia and surgical incision contribute to diaphragmatic dysfunction, reduced lung volumes, impaired mucociliary clearance, and diminished cough effectiveness. These pathophysiological changes create a milieu highly conducive to atelectasis and respiratory infection. Preoperative respiratory muscle weakness, commonly observed in older adults and those with chronic pulmonary disease, further exacerbates this risk. Respiratory muscle prehabilitation seeks to optimize inspiratory and expiratory muscle performance, thereby improving lung volumes, airway clearance, and ventilatory reserve in the critical perioperative period.
Patients most likely to benefit from respiratory muscle prehabilitation are those with increased susceptibility to PPCs. Identified risk factors include advanced age, history of chronic obstructive pulmonary disease (COPD), restrictive lung disease, obesity, smoking, neuromuscular disorders, and reduced cardiopulmonary reserve. Robust risk assessment tools, such as the ARISCAT score and the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) risk calculator, can aid clinicians in stratifying patients and prioritizing those who may derive maximal benefit from prehabilitation protocols.
Preoperative identification of at-risk patients often involves a combination of clinical history, physical examination, functional assessments (such as spirometry and inspiratory muscle strength testing), and evaluation of comorbid conditions. Subtle symptoms of respiratory muscle weakness, including exertional dyspnea, orthopnea, and ineffective cough, may be present but are frequently under-recognized. Objective measures, such as maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP), provide valuable insights into respiratory muscle function and serve as useful baseline parameters for prehabilitation programs.
Comprehensive preoperative evaluation should include detailed pulmonary function testing, assessment of respiratory muscle strength via MIP and MEP, and consideration of adjunctive tests such as arterial blood gases or imaging in selected cases. These diagnostic modalities not only identify individuals at elevated risk for PPCs but also facilitate tailored intervention planning. Emerging technologies, including ultrasound assessment of diaphragmatic movement, may offer additional diagnostic precision in the future.
Respiratory muscle prehabilitation typically involves structured inspiratory muscle training (IMT) protocols, often employing threshold devices that provide graded resistance to inspiratory effort. Programs commonly recommend daily sessions of 15-30 minutes, at intensities of 30-60% of maximal inspiratory pressure, over a period of 2-6 weeks preoperatively. Additional elements may include breathing exercises, incentive spirometry, and patient education on airway clearance techniques. Multidisciplinary involvement—including physiotherapists, respiratory therapists, and perioperative clinicians—is essential for optimal program design, adherence, and outcome monitoring.
Recent studies, including randomized controlled trials and meta-analyses, have reinforced the efficacy of preoperative IMT in reducing the incidence of PPCs, lowering rates of postoperative pneumonia, and decreasing the duration of mechanical ventilation. Novel interventions, such as tele-rehabilitation and app-based training, are expanding access to prehabilitation, particularly for geographically remote or mobility-impaired patients. Precision medicine approaches, incorporating individual risk profiles and real-time monitoring, are under investigation to further refine and personalize respiratory prehabilitation strategies.
Leading perioperative and respiratory societies now recognize the importance of respiratory prehabilitation in high-risk surgical populations. The European Respiratory Society and the American Thoracic Society advocate for the routine assessment of respiratory muscle function and consideration of IMT in preoperative optimization protocols, particularly for those with impaired baseline pulmonary function. Clinical guidelines emphasize the need for individualized program design, appropriate intensity, and multidisciplinary collaboration to maximize benefit and minimize adverse effects.
Respiratory muscle prehabilitation represents a scientifically robust, clinically impactful intervention for reducing pulmonary complications in patients facing high-risk surgery. By enhancing respiratory muscle strength and endurance prior to surgical insult, prehabilitation improves postoperative outcomes, expedites recovery, and optimizes resource utilization. Ongoing research and technological innovation continue to refine this paradigm, supporting its integration into standard perioperative care pathways. Clinicians are encouraged to adopt evidence-based prehabilitation protocols, tailored to individual patient risk profiles, to advance the standard of care for high-risk surgical patients.
1.
Higher levels of HIF2α found to slow down aggressive childhood cancer
2.
Oral drug combination extends progression-free survival in advanced ER-positive breast cancer
3.
Guidelines for cervical cancer screening and the risk of preterm birth in young women.
4.
In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.
5.
Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer
1.
Revolutionizing Cancer Care: The Impact of Darzalex Faspro
2.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
3.
Progressive Models in Hematology for Healthcare Excellence
4.
Quality of Life Following Organ Function Preserving Oncologic Innovation
5.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
2.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation